Which types of diseases are Quizartinib mainly suitable for?

Quizartinib is a new oral FLT3 inhibitor, mainly used to treat adult patients with acute myeloid leukemia (AML) carrying FLT3-ITD mutations. Acute myeloid leukemia is a malignant hematological disease originating from bone marrow hematopoietic stem cells. It develops rapidly and progresses rapidly. FLT3 is a tyrosine kinase receptor that plays an important role in normal hematopoietic cell development. However, when its gene undergoes ITD (internal tandem duplication) mutations, it will lead to continued activation of abnormal signaling pathways, thereby accelerating the proliferation and survival of leukemia cells, and is even associated with poor prognosis.

Quizatinib is specifically designed to targetFLT3-ITD mutations. It is a highly selective second-generation FLT3 inhibitor that has stronger targeting and longer-lasting inhibitory effects than early pan-tyrosine kinase inhibitors. According to approval information from foreign drug regulatory agencies, Quizartinib is currently mainly used for the combined first-line treatment of adult patients with new-onset acute myeloid leukemia carrying FLT3-ITD mutations, that is, in combination with standard chemotherapy drugs such as cytarabine and daunorubicin to enhance the efficacy of induction remission and consolidation therapy.

Although the current indications of quizartinib are mainly focused on patients with FLT3-ITD-positive AML, researchers are also exploring its potential use in patients with relapsed and refractory AML, other subtypes of FLT3 mutations, and patients who have failed multiple lines of treatment. In addition, it is being used in clinical trials in combination with other targeted drugs, immunotherapy or hematopoietic stem cell transplantation, in order to broaden its applicable population.

It is worth noting that quizartinib is not suitable for allAML patients, especially those who do not carry FLT3-ITD mutations, and the efficacy and risks are still unclear. Therefore, before starting to use this drug, it is necessary to use molecular testing to determine whether the patient has relevant mutations. This precision medicine method can help improve the individualization level and success rate of treatment.

Reference materials:https://go.drugbank.com/drugs/DB12874